Revolution Medicines reported survival results from its Phase 3 pancreatic adenocarcinoma study of daraxonrasib, a daily oral KRAS inhibitor. In the trial, patients lived a median of 13.2 months on daraxonrasib versus 6.7 months with standard chemotherapy, according to the readout discussed by STAT+. The company said it intends to use the data to seek FDA approval, with timing dependent on the regulatory path. The result adds a new durability benchmark for KRAS-directed therapy in a disease where resistance has historically limited first-generation KRAS inhibitors. For the broader oncology landscape, the study is already prompting renewed interest in next-generation KRAS programs, with multiple companies pursuing clinical-stage KRAS inhibitors targeting distinct mutant subsets.